股本结构
单位：万股
| 公告日期 | 2023-11-13 | 2023-11-13 | 2023-08-14 | 2023-05-11 | 2023-03-28 | 2023-03-28 |
|---|---|---|---|---|---|---|
| 证券总股本 | 10806.26 | 10716.87 | 10716.76 | 10716.42 | 10716.19 | 10704.39 |
| 普通股本 | 10806.26 | 10716.87 | 10716.76 | 10716.42 | 10716.19 | 10704.39 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-11-09 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2023-03-23 | 2022-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：1
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2023-11-13 | 10806.26 | 未披露 | 定期报告 | 2023-11-09 |
| 2023-11-13 | 10716.87 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of restricted stock units
|
2023-09-30 |
| 2023-08-14 | 10716.76 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of restricted stock units
|
2023-06-30 |
| 2023-05-11 | 10716.42 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of restricted stock units
|
2023-03-31 |
| 2023-03-28 | 10716.19 | 未披露 | 定期报告 | 2023-03-23 |
| 2023-03-28 | 10704.39 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Retirement of treasury shares
Redemption of ordinary shares pursuant to non-recourse secured promissory note
Exercise of options
Conversion of Warrants issued in license agreement into LianBio ordinary shares and LianBio warrants
|
2022-12-31 |
| 2022-08-11 | 10835.38 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Exercise of options
Exercise of warrants
|
2022-06-30 |
| 2022-05-12 | 10827.55 | 未披露 | 定期报告 | 2022-05-10 |
| 2022-03-31 | 10727.55 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of Series A Preferred Shares at $56.66, net of issuance costs
Conversion of preferred shares into ordinary shares upon initial public offering
Issuance of ordinary shares upon initial public offering, net of issuance costs
Conversion of Warrants issued in license agreement into LianBio ordinary shares and LianBio warrants
Exercise of options
|
2021-12-31 |
| 2021-12-09 | 10723.89 | 未披露 | 定期报告 | 2021-12-01 |
| 2021-11-02 | 10525.70 | 未披露 |
更多>>
1.ADSs offered by company 20,312,500 ADSs, each ADS representing one Ordinary Share.
2.Except as otherwise indicated, the number of Ordinary Shares to be outstanding after this offering is based on 84,944,514 Ordinary Shares outstanding as of June 30, 2021
|
2021-11-01 |
From June 30, 2023 to September 30, 2023
Issuance of restricted stock units
From March 31, 2023 to June 30, 2023
Issuance of restricted stock units
From December 31, 2022 to March 31, 2023
Issuance of restricted stock units
From December 31, 2021 to December 31, 2022
Retirement of treasury shares
Redemption of ordinary shares pursuant to non-recourse secured promissory note
Exercise of options
Conversion of Warrants issued in license agreement into LianBio ordinary shares and LianBio warrants
From March 31, 2022 to June 30, 2022
Exercise of options
Exercise of warrants
From December 31, 2020 to December 31, 2021
Issuance of Series A Preferred Shares at $56.66, net of issuance costs
Conversion of preferred shares into ordinary shares upon initial public offering
Issuance of ordinary shares upon initial public offering, net of issuance costs
Conversion of Warrants issued in license agreement into LianBio ordinary shares and LianBio warrants
Exercise of options
1.ADSs offered by company 20,312,500 ADSs, each ADS representing one Ordinary Share.
2.Except as otherwise indicated, the number of Ordinary Shares to be outstanding after this offering is based on 84,944,514 Ordinary Shares outstanding as of June 30, 2021